Exclusive Summary

• With over 236 million peripheral artery disease (PAD) patients globally, an aging population and rising diabetes rates drive rigid, sustained demand for fundamental microcirculation drugs.
• The originator's patents have long expired, eliminating IP barriers and allowing overseas distributors to seamlessly initiate immediate import patterns and local commercialization.
• The 0.4g sustained-release formulation presents a technical barrier that shields it from vicious low-end generic battles, while significantly minimizing gastrointestinal side effects and boosting patient compliance.
• Leveraging China's integrated API-to-formulation supply chain provides overseas agents with rock-bottom procurement costs and massive profit margins, highly advantageous for winning public tender bids.
• The supplier provides ICH-compliant full English CTD dossiers and trusted GMP endorsements, drastically accelerating the regulatory approval timelines in emerging target markets (e.g., LATAM, MENA, ASEAN).